Welcome Message from Conference Co-Convenors
About the Cancer Research Network
Keynote Speakers
National Invited Speakers
Program
Public Lecture
NEW INSIGHTS INTO P53 PATHWAYS FUNCTION : KN01:
INTERCELLULAR COMMUNICATION IN EPIDERMAL CARCINOGENESIS : KN02:
EVALUATING ACCESS AND QUALITY ACROSS THE CANCER CARE CONTINUUM : KN03:
PLASMA DNA-BASED GENOMIC AND METHYLOMIC PROFILING IN CANCER AND PRENATAL DIAGNOSIS: TWO SIDES OF THE SAME COIN : KN04:
INFLAMMATION IN CANCER : S01:
POTENTIAL CLINICAL APPLICATIONS OF CIRCULATING TUMOUR DNA (CTDNA) IN COLORECTAL CANCER : S02:
WHEREFORE ART THOU BIOMARKER(S)?: OPPORTUNITIES FOR PROTEOMICS : S03:
STC1 EXPRESSION IS ASSOCIATED WITH TUMOUR GROWTH AND METASTASIS IN BREAST CANCER : S04:
THE C-CIRCLE ASSAY AS A BLOOD TEST FOR ALT CANCER ACTIVITY : S05:
ONCOGENIC TARGETS IN MELANOMA: WE ARE NOT DONE YET : S06:
CHALLENGES AND OPPORTUNITIES OF USING NEW TECHNOLOGIES IN CANCER MUTATION TESTING : S07:
TARGETED THERAPIES: NEW TARGETS, NEW DRUGS : S08:
TARGETING THE DNA REPLICATION CHECKPOINT BY PHARMACOLOGIC INHIBITION OF CHK1 KINASE: A STRATEGY TO SENSITIZE APC MUTANT COLON CANCER CELLS TO 5-FLUOROURACIL CHEMOTHERAPY : S09:
A NEW TARGETED THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER : P10:
USING GENOMICS TO MAKE A DIFFERENCE – CAN CLINICAL AND POPULATION HEALTH PRACTICE BE CHANGED SO THAT THINGS CAN BE “DONE BETTER”? : S11:
INTEGRATION OF SUPPORTIVE CARE AND CLINICAL RESEARCH – OVERCOMING BARRIERS TO IMPLEMENTATION : S12:
REMOVING THE CANCER EMPEROR'S CLOTHES: HOW RESEARCH MOVED INTO PRACTICE WITH PLAIN TOBACCO PACKAGING : S13:
SMOKING CESSATION AFTER CANCER : S14:
HEALTH SERVICE UTILISATION AND INVESTIGATIONS BEFORE DIAGNOSIS OF CANCER OF UNKNOWN PRIMARY (CUP): A POPULATION-BASED NESTED CASE-CONTROL STUDY : S15:
TARGETED EDVTMNANOCELLS AS VERSATILE VECTORS FOR DELIVERY OF THERAPEUTICS IN CANCER: TRANSLATING A PLATFORM TECHNOLOGY INTO HUMAN CLINICAL TRIALS : S16:
PHOTOPROTECTION BY VITAMIN D COMPOUNDS : S17:
ID4 CONTROLS MAMMARY STEM CELLS AND MARKS BREAST CANCERS WITH A STEM CELL LIKE PHENOTYPE : S18:
LOSS OF VITAMIN D RECEPTOR IN BREAST CANCER CELLS ENHANCES BONE METASTASIS IN A MURINE MODEL OF BREAST CANCER : S19:
CAN ATRX DEFICIENCY BE EXPLOITED FOR ANTI-CANCER THERAPY? : S20:
APPLICATIONS OF MONOCLONAL ANTIBODIES TO DENDRITIC CELLS FOR THE DIAGNOSIS AND TREATMENT OF HAEMATOLOGICAL AND OTHER MALIGNANCIES : S21:
CELL AND GENE THERAPY UPDATE : S22:
CANCER IMMUNOTHERAPY – HOLY GRAIL OR PANDORA'S BOX? : S23:
A SAFETY STUDY TREATING CANINE CANCER PATIENTS WITH AUTOLOGOUS VACCINES : S24:
THE ETS TRANSCRIPTION FACTOR ELF5 IS A KEY DETERMINANT OF THE LETHAL PHENOTYPE IN LUMINAL BREAST CANCER, DRIVING THE ACQUISITION OF ANTIESTROGEN RESISTANCE AND METASTATIC ACTIVITY : S25:
DERIVING CANCER-SPECIFIC UTILITY WEIGHTS FROM THE QLQ-C30: A DISCRETE CHOICE METHODS EXPERIMENT : S26:
AUSTRALIAN IMPLEMENTATION OF SCALP COOLING FOR PREVENTION OF CHEMOTHERAPY INDUCED ALOPECIA : S27:
COGNITION AFTER CHEMOTHERAPY: AN OVERVIEW : S28:
A NEW CONCEPTUAL FRAMEWORK AND CLINICAL STRATEGIES TO MANAGE AND ENHANCE FAMILY INVOLVEMENT IN CANCER CONSULTATIONS : S29:
WHAT'S IN A NAME: HOW DIFFERENT TERMINOLOGY IMPACTS COMMUNITY CONCERN AND TREATMENT PREFERENCES FOR DCIS : S30:
BIG DATA LINKAGES: THE MAGIC BULLET FOR CANCER HEALTH SERVICE RESEARCH? : S31:
WHOLE GENOME METHYLATION SEQUENCING IDENTIFIES POTENTIAL EPIGENETIC- BASED CANCER BIOMARKERS : S32:
MICROTUBULE TARGETS IN CANCER: POTENTIAL OF NANOTECHNOLOGY-BASED THERAPEUTICS : S33:
CANCER PROGRESSION AND RECURRENCE: WHAT WE CAN LEARN FROM EVOLUTIONARY BIOLOGY : S34:
EXPLOITING HSA TO STIMULATE THE DELIVERY AND ANTI-TUMOUR ACTIVITY OF THE ANTI-CANCER THIOSEMICARBAZONE, DP44MT, TO CANCER CELLS : S35:
METASTASIS SUPPRESSOR, N-MYC DOWNSTREAM REGULATED GENE 1 (NDRG1), INHIBITS PRO-SURVIVAL AUTOPHAGIC PATHWAY IN CANCER CELLS : S36:
NON-MUTATED PROTEINS AS TARGETS FOR CANCER THERAPY : S37:
DETERMINING THE EFFECTIVENESS OF TARGETED THERAPIES: CHALLENGES, STRATEGIES AND PITFALLS : S38:
USING PATIENT-DERIVED XENOGRAFTS TO DEFINE ACTIONABLE ABERRATIONS IN HIGH-GRADE SEROUS CANCER : S39:
RESTORING EXPRESSION OF MIR-7 BY TARGETED BACTERIAL MINICELLS INHIBITS THE MAPK/ERK PATHWAY AND OFFERS A NOVEL THERAPY FOR ADRENOCORTICAL CANCER : S40:
TUMOUR SUPPRESSOR FUNCTIONS OF MIR-192 AND MIR-193A-3P IN MALIGNANT PLEURAL MESOTHELIOMA : S41:
THE PROMPT-CARE PROJECT: EHEALTH SYSTEM UTILISING PATIENT REPORTED OUTCOMES TO INFORM PERSONALISED CANCER TREATMENT AND CARE : S42:
A SYSTEMATIC APPROACH TO CLOSING EVIDENCE GAPS IN CANCER CARE : S43:
LUNG CANCER REFERRAL INTERVAL TIMES: A MIXED METHODS STUDY : S44:
AN INTERNATIONAL SURVEY OF AWARENESS OF GENETIC RISK IN THE CLINICAL SARCOMA COMMUNITY : S45:
USING A MULTI- DISCIPLINARY PROGRAM OF CANCER CARE AS A VEHICLE FOR MORE EFFECTIVE RESEARCH TRANSLATION : S46:
TISSUE ENGINEERED HUMANIZED BONE SUPPORTS HUMAN HEMATOPOIESIS IN VIVO : S47:
NOVEL ANTIBODY SCAFFOLDS FOR THERAPY OF SOLID TUMOURS : S48:
APPLICATIONS OF PATIENT-DERIVED SUBRENAL CAPSULE TUMOUR XENOGRAFT MODELS IN MICE : S49:
QUANTITATIVE BIOLOGICALLY GUIDED CANCER TREATMENT USING MULTI-NUCLEAR MAGNETIC RESONANCE IMAGING : S50:
DISTINCTIVE WATER DIFFUSION PROPERTIES OF EPITHELIA MAY BE THE KEY TO BETTER CANCER IMAGING TECHNIQUES : S51:
OESOPHAGEAL ADENOCARCINOMA GENOMICS : S52:
KNOW THY ENEMY: USING GENOMICS TO UNDERSTAND MOLECULAR SUB-TYPES OF EPITHELIAL OVARIAN CANCER : S53:
TARGETED THERAPY RESISTANCE AND IMPLICATIONS FOR PERSONALISED THERAPY IN MELANOMA : S54:
A NEW BETA-CATENIN REGULATORY PATHWAY AS A POTENTIAL TREATMENT TARGET IN COLON CANCER : S55:
POTENTIAL DRIVER GENES OF OVARIAN CARCINOGENESIS IDENTIFIED BY SLEEPING BEAUTY MUTAGENESIS : S56:
TRANSLATING EPIDEMIOLOGICAL RESEARCH IN GYNAECOLOGICAL CANCER INTO CANCER CONTROL : S57:
SURVIVORSHIP CARE FOR PEOPLE WITH COLORECTAL CANCER: A POPULATION-BASED SURVEY OF PATIENTS' EXPERIENCES AND PREFERENCES : S58:
IMPACT OF COMMON GENOMIC VARIANTS ON MELANOMA RISK PREDICTION : S59:
INFORMING WOMEN ABOUT OVERDETECTION OF BREAST CANCER: RANDOMISED TRIAL OF A MAMMOGRAPHY SCREENING DECISION AID : S60:
WHY ARE TWO IN FIVE PROSTATE CANCER CASES RECORDED AS HAVING “UNKNOWN” STAGE OF DISEASE IN AN AUSTRALIAN POPULATION-BASED CANCER REGISTRY? A STUDY OF HEALTH SERVICE FACTORS : S61:
SYNTHESIS AND CHARACTERISATION OF STERICALLY HINDERED PYRIDINE BASED MULTINUCLEAR PLATINUM ANTICANCER COMPLEXES AND THEIR CYTOTOXICITY : P01:
SYNERGISM FROM SEQUENCED COMBINATIONS OF GENISTEIN, CURCUMIN, RESVERATROL, QUERCEITIN AND CAPSAICIN WITH DESIGNED MONOFUNCTIONAL PLATINUMS IN THE KILLING OF HUMAN OVARIAN CANCER CELLS : P02:
MINOCYCLINE REGULATES HYPOXIA-INDUCIBLE FACTOR-1Î ± EXPRESSION THROUGH THE INDUCTION OF ITS DEGRADATION IN OVARIAN CANCER: IN VITRO AND IN VIVO STUDIES : P03:
A NOVEL AMINOACETONITRILE DERIVATIVE, MONEPANTEL (AAD-1566) INHIBITS OVARIAN CANCER CELL GROWTH THROUGH SUPPRESSION MTORC1 AND INDUCTION OF AUTOPHAGY : P04:
STUDIES ON COMBINATIONS OF TARGETED DRUGS WITH TUMOUR ACTIVE PLANT COMPOUNDS IN CANCER : P05:
DEVELOPMENT AND TESTING THE ACCEPTABILITY OF REKINDLE, A WEB-BASED PSYCHOSEXUAL RESOURCE FOR ALL CANCER SURVIVORS AND THEIR PARTNERS : P06:
MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR: A POTENTIAL CELL SURFACE MARKER FOR PROSTATE ONCOGENESIS : P07:
COPPER AND CHEMOTHERAPY TRANSPORTER CTR1, INFLUENCES EMBRYONIC AND TUMOUR DEVELOPMENT : P08:
DIFFERENCE IN CHROMATIN STRUCTURE BETWEEN ALT AND TELOMERASE CANCER CELLS : P09:
MONEPANTEL (AAD556) INDUCES AUTOPHAGY IN HUMAN GLIOBLASTOMA CELLS : P10:
CHARACTERISATION OF A NOVEL TRUNCATED FORM OF CALCIUM-BINDING PROTEIN S100P AND ITS POTENTIAL ROLE AS A PROGNOSTIC MARKER IN BREAST CANCER : P11:
DO CANCER PATIENTS DISTINGUISH BETWEEN THE IMPORTANCE AND SEVERITY OF THEIR QUALITY OF LIFE CONCERNS? : P12:
THE DEVELOPMENT OF CANCER-SPECIFIC MULTI-ATTRIBUTE UTILITY INSTRUMENTS FROM THE EORTC QLQ-C30 AND FACT-G : P13:
SAFEGUARDING RADIOTHERAPY CANCER TREATMENT: MEASURING RADIATION DOSE IN THREE DIMENSIONS : P14:
STEM CELL APPROACH TO GENERATE MULTIPLE IMMUNE EFFECTOR CELLS TO TREAT CANCER : P15:
BRAF V600E MUTATION STATUS AND ASSOCIATED HISTOPATHOLOGY FEATURES IN PAPILLARY THYROID CARCINOMA: A COMPARISON OF NEW CALEDONIA AND AUSTRALIAN POPULATIONS : P16:
P17 DEVELOPMENT OF AN INTERVENTION FOR COMMUNICATING PERSONAL GENETIC RISK OF MELANOMA TO THE GENERAL PUBLIC
EPITHELIAL CELL MOVEMENT AND NUCLEAR AND CYTOPLASMIC FORMS OF THE ESSENTIAL PROTEASE DIPEPTIDYL PEPTIDASE 9 (DPP9) : P18:
VITAMIN D3 (CHOLECALCIFEROL) ACTS AS A NEGATIVE REGULATOR OF BREAST CANCER CELL INVASIVENESS IN THE ABSENCE OF ACTIVATION OF CLASSICAL VDR SIGNALLING : P19:
GOAL PROCESSES, COPING, AND ADJUSTMENT IN YOUNG ADULTS WITH TESTICULAR CANCER : P20:
DRY EYES & AIS : P21:
RAC1 ACTIVATION CAUSES A REDISTRIBUTION OF β-CATENIN-RAC1 COMPLEXES FROM MEMBRANE TO NUCLEUS: A NEW MODEL FOR RAC1 STIMULATION OF WNT SIGNALLING IN CANCER : P22:
THE ROLE OF MDTS IN SUPPORTING RESEARCH TRANSLATION : P23:
A RARE CASE OF CUTANEOUS MULTIPLE MYELOMA : P24:
TARGETED TREATMENT OF LUNG CANCER USING SILK-BASED DRUG CARRIERS : P25:
CLOSING THE GAP BETWEEN RESEARCH, BIOBANKS AND CLINICAL PRACTICE: A 12 MONTH EXPLORATORY STUDY INTO DEVELOPING A STANDARD PRE-OPERATIVE MODEL FOR OBTAINING BIOBANK CONSENT : P26:
SYNTHESIS AND IN-VITRO EVALUATION OF ANTICANCER RH(III) COMPLEXES : P27:
THE SYNTHESIS AND BIOLOGICAL STUDY CURCUMIN ANALOGUES AS ANTICANCER AGENTS : P28:
ROLE OF FOCAL ADHESION KINASE IN GLIOMA STEM CELLS : P29:
INCREASING PREVALENCE EXPECTATION IN THORACIC RADIOLOGY LEADS TO OVERCALL : P30:
THE CHARACTERISATION OF APC LOCALISATION, DYNAMICS AND FUNCTION AT THE CENTROSOME : P31:
ACCURACY OF ULTRASOUND DURING NEOADJUVANT THERAPY FOR BREAST CANCER TO PREDICT PATHOLOGIC RESPONSE : P32:
DEFINING A MOLECULAR “SWITCH” IN COLON CANCER: REGULATION OF THE BETA-CATENIN DEGRADATION COMPLEX : P33:
THE ROLE OF SPECIFIC BARD1 SPLICE VARIANT ISOFORMS IN BREAST CANCER CELL RESISTANCE TO DNA DAMAGING AGENTS : P34:
THE METASTASIS SUPPRESSOR NDRG1 DOWN-REGULATES THE EXPRESSION OF SNAIL AND SLUG TO PROMOTE E-CADHERIN EXPRESSION IN PANCREATIC CANCER : P35:
MODE OF ADMINISTRATION OF PATIENT-REPORTED OUTCOMES (PRO) MEASURES: A SYSTEMATIC REVIEW : P36:
INVESTIGATION OF THE GENETIC PREDISPOSITION TO CANINE LYMPHOMA : P37:
3D TISSUE CULTURE- A MORE EFFICIENT AND PREDICTIVE MODEL FOR THE ASSESSMENT OF EDVTMNANOCELL DELIVERY TO TUMOURS : P38:
LEGITIMACY OF FUNDING DECISIONS FOR CANCER MEDICINES: A THEMATIC ANALYSIS OF STAKEHOLDER PERSPECTIVES : P39:
COSTS OF CANCER CARE AT THE END OF LIFE : P40:
RESOURCE USE IN THE LAST 180 DAYS OF LIFE IN THE ELDERLY DECENDENTS : P41:
A CANCER RISK-ASSOCIATED POLYMORPHISM IN THE TERT LOCUS ENCODES A NOVEL SPLICE VARIANT WHICH IS A DOMINANT NEGATIVE INHIBITOR OF TELOMERASE : P42:
IMPLEMENTING A CLINICAL PATHWAY FOR CANCER ANXIETY, DEPRESSION AND DISTRESS: WHAT DOES A QUALITATIVE ANALYSIS TELL US ABOUT BARRIERS AND ENABLERS? : P43:
STRUCTURAL FEATURES OF BROAD-SPECTRUM ANTI-CANCER BAMLET COMPOUNDS : P44:
THE IMPACT OF DUCTAL CARCINOMA IN SITU (DCIS) OF THE BREAST ON PATIENT-REPORTED OUTCOMES (PROS): A SYSTEMATIC REVIEW : P45:
THE ROLE OF TRANSITION METALS IN PROTEIN PHOSPHORYLATION IN HUMAN HEALTH AND DISEASES : P46:
ANTITUMOUR ACTIVITY OF WEDELOLACTONE, BETULINIC ACID AND EPIGALLOCATECHIN-3-GALLATE (EGCG) IN OVARIAN CANCER CELL LINES : P47:
OBESITY-RELATED BREAST TUMORIGENESIS IN RESPONSE TO A HIGH-FAT DIET IS RELATED TO INCREASED MAMMARY FAT PAD MASS : P48:
INVESTIGATING THE ROLE OF LONG NON-CODING RNAS IN CISPLATIN RESISTANCE IN OVARIAN CANCER : P49:
SOCIOECONOMIC DISPARITIES IN SURVIVAL OVER TIME FOR 10 MAJOR CANCERS IN NEW SOUTH WALES, AUSTRALIA: 1996–2008 : P50:
Anthropogenic selection enhances cancer evolution in Tasmanian devil tumours : P51:
TARGETED DELIVERY OF PLATINUM DRUGS TO TUMOURS USING CARRIER DNA-TETHERED APTAMERS : P52:
THYROID FNA BRAF POSITIVITY CORRELATES WITH A HIGHER GRADE BETHESDA CATEGORY : P53:
INTEGRATIVE ANALYSIS OF MRNA EXPRESSION PROFILES IDENTIFIES NOVEL TARGETS FOR THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) : P54:
DIPEPTIDYL PEPTIDASE 9 HAS ROLES IN CELL ADHESION AND MIGRATION OF HEPATOMA CELLS : P55:
ENDOCYTOSIS IN MITOSIS: THE ROLE OF SNX9 IN CYTOKINESIS : P56:
TEN YEAR REVIEW OF THE WAIKATO EXPERIENCE OF MICROCYSTIC ADNEXAL CARCINOMA: A RARE BUT SIGNFICANT HEAD AND NECK TUMOUR : P57:
DELETERIOUS PASSENGER MUTATIONS AS A BIOMARKER FOR HEPATOCELLULAR CARCINOMA : P58:
THE P38-MK2-HUR PATHWAY POTENTIATES EGFRVIII-IL-1β-DRIVEN IL-6 SECRETION IN GLIOBLASTOMA CELLS : P59:
INTRODUCING DRUG DELIVERY VEHICLE IN ALBENDAZOLE DECREASES TUMOR BURDEN, REDUCES VEGF AND INHIBITS ASCITES IN OVARIAN CANCER XENOGRAFT MODEL : P60:
Sponsors and Exhibitors
General Information
Conference Venue